Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study

W. Busse (Madison, WI, United States of America), E. Bleecker (Tucson, AZ, United States of America), J. Fitzgerald (Vancouver, BC, Canada), G. Ferguson (Farmington Hills, MI, United States of America), P. Barker (Gaithersburg, MD, United States of America), S. Sproule (Gaithersburg, MD, United States of America), R. Olsson (Gothenburg, Sweden), M. Goldman (Gaithersburg, MD, United States of America), U. Martin (Gaithersburg, MD, United States of America), On Behalf Of The Bora Study Investigators

Source: International Congress 2018 ā€“ Notable Studies in Asthma
Session: Notable Studies in Asthma
Session type: Oral Presentation
Number: 3567
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Busse (Madison, WI, United States of America), E. Bleecker (Tucson, AZ, United States of America), J. Fitzgerald (Vancouver, BC, Canada), G. Ferguson (Farmington Hills, MI, United States of America), P. Barker (Gaithersburg, MD, United States of America), S. Sproule (Gaithersburg, MD, United States of America), R. Olsson (Gothenburg, Sweden), M. Goldman (Gaithersburg, MD, United States of America), U. Martin (Gaithersburg, MD, United States of America), On Behalf Of The Bora Study Investigators. Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study. 3567

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: